References
- Grinspoon L., Bakalar J. B. Marihuana, the Forbidden Medicine, revised and expanded edition. Yale University Press, New Haven 1997
- Singh G., Ramey D. R., Morfeld D., Shi H., Hatoum H. T., Fries J. F. “Gastrointestinal Tract Complications of Nonsteroidal Anti-inflammatory Drug Treatment in Rheumatoid Arthritis”. Archives of Internal Medicine July 22, 1996; 156: 1530–1536
- Perneger T. V., Whellon P., Kjag M. J. “Risk of Kidney Failure Associated With the Use of Acetaminophen. Aspirin, and Non-steroidal Anti-inflammatory Drugs”. New England Journal of Medicine December 22, 1994; 331(5)1675–1679, P. M. Ronco and A. Flahault, “Drug-induced End-stage Renal Disease”, Editorial. New England Journal of Medicine, 331: 25 (December 22, 1994): 1711-1712.
- Lasagna L. “Clinical Trials in the Natural Environment”. Drugs Between Research and Regulations, C. Stiechele, W. Abshagen, J. Koch-Weser. Springer-Verlag, New York 1985; 45–49
- Larson E. B. “N-of-1 Clinical Trials: A Technique for Improving Medical Therapeutics”. Western Journal of Medicine January, 1990; 152: 52–56, G. H. Guyatt, J. L. Keller, R. Jaeschke, et al., “The N-of-1 Randomized Controlled Trial: Clinical Usefulness,” Annals of Internal Medicine 112 (1990): 293-299.
- “State Multiple Prescription Programs,”. State Health Legislation Report of the American Medical Association August, 1988; 15: 35–339
- Schwartz H. I. “Negative Clinical Consequences of Triplicate Prescription Regulation of Benzodiazepines,”. Hospital and Community Psychiatry April, 1992; 43: 382–385, M. Weintraub, S. Singh, L. Byrne, et al., “Consequences of the 1989 New York State Triplicate Benzodiazepine Prescription Regulations,” JAMA 266 (1991): 2392-2397; R. S. Hoffman, M.G. Wipfler, M.A. Maddaloni, et al., “Has the New York State Triplicate Benzodiazepine Prescription Regulation Influenced Sedative-Hypnotic Overdoses?” New York State Journal of Medicine 91 (1991): 436-439.